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Abstract
Background: To determine if tropism for CXCR4 or CCR5 correlates with cellular HIV DNA load, residual viraemia
and CD4 count in 219 successfully treated naive subjects with HIV infection enrolled in five infectious diseases units
in Northeastern Italy.
Methods: A subset of subjects, achieving plasma HIV RNA level <50 copies/ml after initiation of first-line therapy
and maintaining it until follow-up time points, was retrospectively selected from a prospective cohort. Blood
samples were collected before the beginning of therapy (T0), at the first follow-up time (T1) and, when available,
at a second (T2) follow-up time.
Results: HIV DNA, CD4 count and plasma viraemia were available from all 219 patients at T0 and T1, and in 86 subjects
at T2, while tropism determinations were available from 109 subjects at T0, 219 at T1, and from 86 subjects at T2.
Achieving residual viraemia <2.5 copies/ml at T1 correlated with having the same condition at T2 (p = 0.0007). X4
tropism at T1 was negatively correlated with the possibility of achieving viraemia<2.5 copies/ml at T2 (p = 0.0076).
T1-T2 tropism stability was significant (p <0.0001). T0 tropism correlated with T1 and T2 tropism (p < 0.001); therefore
the stability of the tropism over the two follow-up periods was significant (p = 0.0003). An effective viremic
suppression (viraemia<2.5 copies/ml) correlated with R5 coreceptor affinity (p= 0.047).
Conclusions: The tropism of archived virus was stable during an effective treatment, with 15-18% of subjects
switching over time, despite a viraemia<50 copies/ml. R5 tropism and its stability were related to achieving and
maintaining viraemia<2.5 copies/ml.
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Background
Several chemokine receptors are coreceptors for HIV
entry into cells. Non-syncytium-inducing HIV variants use
the CC-chemokine receptor (CCR)-5 as a coreceptor (R5
viruses) [1-4], whereas syncytium-inducing HIV variants
use the CXC-chemokine receptor (CXCR)-4 (X4 viruses)
and, in some cases, sometimes, in addition, CCR-5 (dual/
mixed or D/M viruses) [5]. The co-receptors CCR5 and
CXCR4 are both expressed in the cell and tissue targets of
HIV, consistent with their roles in disease transmission
and progression [6]. The R5 viruses are generally predom-
inant in the early stages of HIV infection, whereas the
emergence of X4 viruses generally occurs in the later stage
[7-9]. The presence of X4 viruses is consistently associated
with low CD4 T-cell counts and accelerated disease
progression, although it is unclear whether the presence
of X4 viruses is a cause or consequence of disease progres-
sion [6,7].
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The dynamics and the influence of viral tropism on
the course of HIV-1 infection in subjects exposed to
antiretroviral therapy (ARV) are not fully understood.
Several studies have demonstrated a higher prevalence
of X4 variants in patients exposed to antiretroviral drugs
than in drug-naïve individuals [10,11]. The studies that
have attempted to correlate viral tropism with the
response to ARV have generally demonstrated no differ-
ences in the response to treatment between patients
harbouring an X4- or R5-tropic virus, although a poor
recovery in the number of CD4+ cells has been shown
in patients with an X4-tropic virus before the beginning
of treatment or in PBMCs (peripheral blood mono-
nuclear cells) after treatment [1,12,13]. The presence of
an X4-tropic virus has been demonstrated to have a
deleterious effect on CD4 cell count growth and the risk
of clinical disease in patients undergoing the first line of
HAART (Highly Active Antiretroviral Therapy) [7].
Studies aimed at assessing the influence and frequency
of the switch of viral tropism during the course of
therapy showed a low event rate in patients responding
to HAART, and there have been conflicting results
regarding the response to treatment, even if a direct
correlation between the switch from an R5- to an X4-
tropic virus and a low CD4 + nadir was found in treated
patients [14-17].A change in viral tropism has been
shown to occur in patients during ARV interruption,
and the switch from an R5-tropic to an X4-tropic virus
is associated with a previous heavy treatment experience,
a considerable decrease in the CD4 cell count and a
shorter length of treatment interruption [18,19].
Up to now, there are few data from longitudinal studies
on viral tropism in patients fully responding to HAART,
and in particular, there are insufficient data on the corre-
lation between viral tropism and combined HIV-proviral
DNA, residual viraemia and drugs used in treatment.
To assess the impact of antiretroviral therapy on viral
tropism evolution and the correlations between tropism
and the response to therapy in terms of HIV DNA and
residual viraemia values, we retrospectively examined a
group of 219 HIV-1-infected naïve individuals who were
successfully treated with ARV.
Methods
Study design
The CAVeAT is a prospective cohort of HIV-infected
patients enrolled starting from 2004 in five infectious
diseases units in Northeastern Italy (Veneto region). We
retrospectively selected from this cohort of patients a
subset of subjects achieving virological suppression
within 6 months after initiation of first-line therapy and
maintaining plasma HIV RNA levels < 50 copies/ml,
without virological failures, until evaluation at the
follow-up time points. Patients interrupting or needing
treatment modifications for failure, as well as patients
who had more than one viral blip (plasma HIV RNA
from 50 to 1.000 copies/ml) per year after achieving viral
suppression, which was determined by frequent blood
sampling (at least 4 times per year), were not included
in the study. In the event of a change in the HAART, it
was accepted if this change was due to intolerance or pill
burden convenience. No patient was treated with CCR5
antagonists.
Blood samples were collected at baseline (before the
beginning of therapy), at the first follow-up time (T1)
and, when available, at a second (T2) follow-up time.
First follow up time (T1) was defined as the first available
time point after achieving virological suppression within a
range from 12 to 72 months, and T2 as a more recent
time point available, collected a median time of 16 months
after T1. All virological and immunological analyses were
performed on all samples, with the exception of the trop-
ism analysis, which was performed on all samples available
at T1 and T2 but on only 109 out of 219 subjects at T0
due to depletion of the samples. This cohort was initially
enrolled for another study on DNA load [20].
The enrolled subjects gave informed consent for all
procedures and the use of their blinded data for a scien-
tific evaluation and publication. The local government,
which was represented by the Veneto Regional Health
Authority, approved the study and provided funding
(Regional Government Decree 3643/2004 and 3499/2008).
This study was conducted in accordance with the Helsinki
Declaration and local legislation (Ethics Committee of
Padova University Hospital prot. 2606-12P).
A primary HIV infection was defined by (i) a negative
or indeterminate HIV antibody enzyme linked immuno-
sorbent assay associated with HIV RNA positive plasma
or (ii) an initially negative test for HIV antibodies followed
by a positive serology within 18 months.
The blood samples were collected in tubes containing
EDTA and separated into plasma and cells using Ficoll-
Paque Plus density gradient centrifugation. Aliquots of
plasma and dried pellets of 2 × 106 PBMCs were stored
at −80°C until use. Baseline and follow-up blood samples
in EDTA were submitted within 6 hours from collection
to the Laboratory of Virology at the University of Padova
and stored until analysis.
Cellular HIV DNA quantitation
The extraction and purification of DNA from cells were
performed using the QIAmp Blood kit (Qiagen, Inc.,
Chatsworth, CA). The real-time TaqMan protocol was
used to quantify the cellular HIV DNA copy number in
PBMCs as previously described [20]. The cell line 8E5,
which contains one copy of integrated HIV DNA in each
cell, was used to build a standard curve with a sensitivity
of 5 copies/million PBMCs [21].
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A duplicate analysis within the same experiment was
conducted for both HIV and beta-globin evaluation, and
the mean of these values was calculated. When the delta
values were more than 10%, the sample was analysed
again. Baseline and follow-up samples from a patient
were always evaluated in the same experiment; this
procedure was possible because only complete sample
sets (T0 and T1, and T2 when available) of the patients,
retrospectively selected, were considered. A sample that
had been previously evaluated was regularly added as an
internal control.
Quantification of plasma residual viraemia
The plasma samples were obtained from the blood that
was collected and were frozen at −80°C within 6 hours
of collection and kept at this temperature until testing.
Residual viraemia was quantified, using an ultra-
ultrasensitive method based on a modified Amplicor HIV-
1 Monitor test, version 1.5 (Roche Molecular Systems,
Branchburg, New Jersey, USA), with a limit of detection
limit of 2.5 copies/ml [20]. Modifications included pelle-
ting viruses from 2 ml of plasma at 23.600 g at 4°C for
2 hours, adding half of the normal volume of the quan-
tification standard and resuspending the RNA pellet in
50 ul of diluent. The entire volume of the resuspended
RNA was assayed, using reverse transcription and PCR
amplification. These and subsequent detection steps
followed were performed according to the manufac-
turer’s protocol.
Genotypic prediction of viral tropism
Genotypic analysis of viral tropism was performed on
PBMCs as previously described [22]. Briefly, the V3
sequences were amplified using nested PCR with 1F1 and
1R1 as the outer primers and 3F3 and 2R2 as the inner
primers.We checked the number of ambiguities examined
before running geno2pheno: they were considered rele-
vant if the number was greater than two. In that case the
sequencing was repeated and the sample was excluded if
the ambiguities were confirmed. Seven samples met this
criteria and the seven patients were not included. When a
single or double ambiguity gave discordant results in
terms of FPR, sequencing was repeated.
The generated V3 sequences were then interpreted
using the bioinformatic tool Geno2pheno, with a false-
positive rate of 20%. Geno2pheno is available at http://
coreceptor.bioinf.mpi-inf.mpg.de (accessed by June 2012).
All PBMCs available from the subjects gave a useful
amplification and sequencing of the V3 region, allowing
us to analyse all subjects.
All longitudinal discordant results were analysed twice,
to confirm the tropism switch; similarly, all samples with
an false positive rate from 10% to 30% were confirmed
by a second analysis starting from the amplification of
the sample. In summary, we determined and described a
clear viral switch only with two concordant predictions.
Statistical analysis
The following variables were analysed: age, CD4 cell count
at T0 and follow-up, and HIV DNA log10 copies/10
6
PBMCs at T0 and follow-up. The HIV RNA log10 copies/
ml was evaluated as continuous variable. HIV RNA at
follow-up under the lowest threshold level (under 2.5 cop-
ies/ml), primary HIV infection at the start of therapy,
stranger origin, male gender, risk categories (heterosexual,
men who have sex with men, drug addiction) and tropism
based on the presence of R5 or X4 variants in PBMCs at
T0, T1 and T2 were evaluated as binary variables.
All variables were submitted to pairwise correlation
analysis to outline the underlying link pattern in the
evaluated population. The correlation was established by
a linear regression analysis when at least one variable
was continuous. When both paired variables were
categorical (binary), the chi-square test by Pearson or
the Fisher’s exact test (when applicable) were used.We
performed a further statistical analysis based on X4
detection and R5 detection as binary variable and the
patient as grouping variable (most patients had repeated
observations). Unifying the time-points under a common
time scale, a multilevel/mixed logistic regression was
performed, using plasma RNA under low threshold as
outcome, and the following covariates: log10DNA,
baseline log10RNA, X4R5 (binary variable), and time.
Conventional descriptive statistics were also applied
when appropriate.
Results
Tropism analysis at T1
The sequences from the PBMCs of 219 patients were geno-
typed at a median follow-up of 36 months (range 12–72)
after the initiation of therapy. The demographic, virological
and immunological data are reported in Table 1.
Of the 219 subjects, 146 (66.6%) had an R5 genotype in
PBMCs. Eighty-three of 219 subjects (37.9%) had < 2.5
copies/ml of HIV RNA at T1. In particular, 62 of 146
patients (42.4%) harbouring a R5-tropic virus and 21
of 73 patients (28.7%) with an X4 virus reached fewer
than < 2.5 copies/ml of HIV RNA (p=ns). The analysis
of viro-immunological parameters before starting
HAART showed a significantly higher CD4 cell count
at baseline in R5 than in X4 patients (median values
284 cells, range 0–810, vs. 201 cells, range 7–1090,
p= 0.0216).
Tropism analysis of patients with T0 and T1 evaluations
A tropism analysis of PBMCs at the baseline of therapy
(T0) was available in 109 of 219 subjects from the study
population.
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At the T0, 75 subjects (69%) had R5 tropism. The sub-
jects harbouring an X4-tropic virus had a lower baseline
CD4 absolute count than the patients with an R5-tropic
virus (p= 0.0012) and higher baseline plasma HIV RNA
levels (p = 0.0431). With regard to the genotype stability,
the results showed that at T1, after a median time of 24
months of follow up (range 12 – 48), most patients (89 out
of 109, 81.6%,) maintained the same viral tropism. (Table 2):
12 out of 75 R5 subjects (16%) switched to X4.
No differences in the follow-up duration were
observed between the patients harbouring an R5- or an
X4-tropic virus or between the switching or non-
switching subjects (data not shown). The subjects with a
stable X4 virus had a median CD4 cell gain of 235 cells
(increased from 185 to 420 cells), and the patients with
a stable R5 virus had a CD4 cell gain of 237 cells (from
305 to 542 cells). The patients who switched to an X4
virus presented a CD4 cell gain of 197 cells (from 228 to
425 cells), whereas the patients who switched to an R5
virus had a CD4 cell gain of 496 cells (from 104 to 600
cells). The patients with a stable X4 virus showed a
decrease in HIV DNA from 516 to 58.5 copies/106
PBMCs (median values), and the patients with a stable
R5 virus showed a decrease in HIV DNA from 896 to
127 copies/106 PBMCs.The patients who switched to an
X4 virus showed a decrease in HIV DNA from 1432 to
159 copies/106 PBMCs, and the patients who switched
to an R5 virus showed a decrease in HIV DNA from
419.5 to 111 copies/106 PBMCs.
At T1, 42.3% (11/26) of the patients with a stable X4
virus, 46% (29/63) of the patients with a stable R5 virus,
16.6% (2/12) of the patients who switched to an X4 virus
and 43% (3/8) of the patients who switched to an R5
virus reached fewer than 2.5 copies/ml of HIV RNA
(p = ns).
Tropism analysis of patients with T1 and T2 evaluation
A second evaluation of HIV tropism and of viro-
immunological parameters was obtained in 86/219 subjects
at T2 (median time of 16 months after T1). An R5 tropic
strain was detected in 5 patients (67%) (Table 3). In 73 out
Table 1 Demographic, virological and immunological data for the entire population and the R5 and X4 subgroups, as
identified by genotyping at T1
All patients R5 subgroup patients X4 subgroup patients p
Number 219 146 73 ns
Male (n) 173 118 55 ns
Italian (n) 180 114 66 ns
Agea (years) 41 (19–79) 40 (19–74) 43 (21–79) p= 0.0332
Riskb
Heterosexual (n) 91 60 31 ns
MSM (n) 67 47 20 ns
Drug user (n) 18 11 7 ns
Missing (n) 43 28 15 ns
Subtype-B (n) 171 113 56 ns
Primarycn (%) 29 (13.2%) 21 (14.3%) 8 (11%) Ns
T0 CD4 cells/mm3a 260 (0–1090) 284 (0–810) 201 (7–1090) p= 0.0216
T0 CD4%a 16 (0–39) 17 (0–37) 13 (1–39) ns
T0 HIV RNAa copies/ml 101836 (412–1x107) 101836 (412–1x107) 1000182 (547–6258236) ns
T0 HIV DNAa, d 1198 (33–70123) 1185 (70–18856) 1297 (33–70123) ns
T1 CD4 cells/mm3a 560 (54–1330) 580 (54–1306) 485 (96–1330) ns
T1 CD4%a 28.9 (3.4–55.2) 29.9 (3.4–55,2) 26 (5–51.9) ns
T1 HIV RNA<2,5 copies/ml n (%) 83 (37.9%) 62 (42.4%) 21 (28.7%) ns
T1 HIV DNAa, d 107 (5–892) 105 (5–892) 110 (5–740) ns
aExpressed as median and range.
bTransmission risk reported as prevalent.
c Being in HIV Primary Infection at the start of therapy.
d Copies/106PBMCs.
Table 2 R5 and X4 tropism at T0 and T1
R5 T1 (n) X4 T1 (n) Total
R5 T0 (n) 63 12 75
X4 T0 (n) 8 26 34
Total 71 38 109
(Persistence of the tropism: 82% Pearson chi2(1) = 37.6715, P<0.001). Eighty-
nine subjects didn’t switch.
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of 86 patients (p<0.0001) no modification of viral tropism
occurred from the T1 to the T2 time point.
Six of the57 subjects harbouring an R5 virus at T1
switched to an X4 virus at T2, whereas seven of 22
patients with an X4 virus switched to an R5 virus at T2.
No differences in the follow-up duration were observed
among the four groups of patients. The ability to reach
the lowest threshold of plasma HIV RNA at T1 correlated
with having the same viral tropism at T2 (p = 0.0007).
With respect to the correlation of residual viraemia with
viral tropism, a condition of X4 tropism at T1 was nega-
tively correlated with the possibility of reaching virological
success with plasma RNA under the lowest threshold at
the second time point (p= 0.0076). The relation among
tropism evolution from T1 to T2 and the detection of
plasma viremia lower than 2.5 copies/ml at T2 is reported
in table 3 (p = 0.009). No differences in the therapy
regimens were found among the groups (data not shown).
The mean CD4 cell increase from T1 to T2 was sig-
nificantly higher for R5 harbouring patients (p = 0.0497).
Similarly, the persistence of HIV RNA less than 2.5
copies/ml at T1 and T2 was detected in non-switcher
patients. In stable R5 patients, the persistence of an
undetectable viral load was 76% (p = 0.002).
Tropism analysis in patients with T0, T1 and T2 evaluations
In a subgroup of 51 patients, a viral tropism evaluation
of the PBMCs at all 3 time points T0, T1 and T2 was
available.The stability of the tropism over the long follow
up, from T0 to T2, was significant (p = 0.0003).
Six of the 37 R5 patients at T0 switched to X4 at T2.
In the evaluation of the sequence of the coreceptor trop-
ism status of the patients at the three time points, 5 of the
8 subjects with plasma RNA levels below 2.5 copies/ml at
T2 were stable R5, one was R5-R5-X4, one was R5-X4-R5,
and one was X4-R5-X4 ( p= ns).
Twenty-four percent of patients that were stable R5
from T0 to T2 had less than 2.5 copies of HIV RNA,
compared to none with a stable X4.
A significant persistence (p = 0.047) of the virological
effect, defined as reaching the <2.5 copies RNA level at
T1 and maintenance at T2, was noted in non-switcher
patients with R5 virus.Overall, 9 R5 patients had un-
detectable viremia at T1 and 5 confirmed virological
success at T2.An RNA level below the lowest threshold
at T1 and T2 was found in subjects with persistence of
the R5 status at the transition from T0 to T1. The per-
sistence of the acquired RNA level was 73% (p = 0.047).
The baseline X4 condition was correlated with lower
values of cellular HIV DNA, both at T1 (p= 0.0288) and at
T2 (p= 0.0095). HIV DNA levels (p=0.002) and the condi-
tion of having a primary infection at the start of therapy
(p= 0.008) were related to attaining RNA virological
success, defined as having <2.5 copies/ml of HIV RNA.
Quality control
A total 47 patients had a FPR between 10-20%: 10 (9.2%)
in the group of 109 patients evaluated at T0, 24 (11%) in
the group of 219 patients with tropism available at T1
and 13 (15.1%) in the group of 86 patients studied at T2.
Overall, 6 out of 21 (28.6%) patients with an FPR > 10%
and 9/42 (21.4%) with an FPR < 10% switched to R5.
Multilevel/mixed logistic regression
The multilevel/mixed logistic regression confirmed that
R5 is independently correlated to the achievement of
plasma HIV RNA under 2.5 copies/ml.
Three covariates appeared negatively correlated to the fa-
vorable virological outcome: log10DNA, baseline log10RNA,
X4R5 in a significant manner. The coefficients of the
regression are reported in Table 4.
Discussion
This study is the first to analyse the relationship of trop-
ism of archived virus with residual plasma viraemia
below 2.5 copies/ml and HIV DNA cellular load in a co-
hort of naïve patients who underwent and mantained
successful treatment, with a baseline and two follow-up
time points. The observation time was prolonged, with a
median of 36 months from the beginning of treatment
and 16 months thereafter in a subgroup of patients.
The stability of tropism in 109 subjects from the
beginning of therapy to a median follow-up point of 24
months was significant (p< 0.001), with 89 subjects (82%)
Table 3 DNA and CD4 evolution in 86 patients followed from the T1 to the T2 time point and detection of residual
viraemia at T2
Patients (n)** Stable X4 (22) Stable R5 (51) Switch to X4 (6) Switch to R5 (7)
CD4 T1a cells/mm3 431 (130 – 950) 560 (54 – 1170) 600 (330 – 860) 420 (315 – 890)
CD4 T2a cells/mm3 520 (170 – 1110) 615 (92 – 1291) 540 (290 – 970) 535 (420 – 740)
HIV DNA T1a Copies/106PBMCs 41 (<5 – 657) 95 (<5 – 892) 75.5 (<5 – 532) 196 (18 – 424)
HIV DNA T2a Copies/106PBMCs 50.5 (<5 – 448) 83 (<5 – 469) 31 (<5 – 412) 70 (7 – 147)
HIV RNA <2,5 copies/ml (n/total n patients and percentage)b 2/22 (9.1%) 19/51 (37.2%) 4/6 (66.7%) 1/7 (14.3%)
aExpressed as median and range.
b Pearson chi2 (3)=11.5664, P = 0.0009).
** The stability of the tropism (stable X4 plus stable R5 vs switch to R5 plus switch to X4) was significant p< 0.0001.
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remaining in the same condition as that at the baseline, 8
subjects switching to R5 and 12 subjects switching to X4.
A higher stability of viral tropism (88%) during ARV was
previously reported [15] in a smaller cohort, with 12%
switching in either direction. Interestingly, a successful
amplification result could be obtained for only 33 out of
53 subjects, with respect to 100% of our cohort. Soulié
et al.correlated the DNA and plasma RNA genotypes of
fully responding patients after 2 years of therapy and
found a stable genotype in 92.9% of subjects [16]. In their
study, the switch in viral tropism is demonstrated by
looking at the difference in the viral genotypes in the sam-
ples of cellular DNA during successful therapy and plasma
RNA, collected at the time of detectable viraemia. In our
study, the switch in viral tropism was assessed using the
cellular DNA samples collected longitudinally at different
times from patients who fully responded to ARV, and
therefore, the results can be difficult to compare. Further-
more, it has been previously demonstrated that the viral
genotypes of the strains stored in DNA compared to that
detectable in the plasma during replication may be differ-
ent [22]; this finding casting doubts about the reliability of
the results of Soulie’s study.
The stability of tropism remained significant in the
second period of observation (T0 to T2 p = 0.0003); in
the second follow-up interval, 16% of the subjects
switched, and a correlation between a switch to X4 and
a decrease in the CD4 count was observed. No differ-
ences in relation to the therapy administered at the time
of follow-up were observed in the different groups.
The emergence of X4 viruses generally occurs in the
later stages of disease [7-9], and it is associated with low
CD4 T-cell counts. Several studies have demonstrated a
higher prevalence of X4 variants in patients exposed to
antiretroviral drugs than in drug-naïve individuals [10,11].
Delobel et al. suggested that the emergence of X4 variants
on HAART may be due to the preferential implication of
X4 variants in cellular reservoirs, either through a pro-
gressive replenishment of the pool of resting memory
CD4+ T cells by cells derived from long-lived naive CD4+
T cells harboring archival X4 species, or through the
preferential residual replication of X4 viruses on HAART.
About the relation among this potentially selective replica-
tion of strains with different tropism in various immuno-
virological conditions, we investigated the residual viral
replication in our patients.
Among 219 successfully treated subjects, 38%
reached complete control of viral replication, defined
as an HIV RNA copy number under the detection
limit of 2.5 copies/ml, by the first follow-up. This rate
is comparable with those of other studies reporting suc-
cess rates of 36-40%, but it is lower than that of another
cohort study reporting a success rate 60% [20,23]. A
significant persistence of the acquired lowest RNA level
was observed (p= 0.002). The patients harbouring an X4
strain at T1 were less able to reach this virologic success
at T2 (p= 0.0076). Of note, 40% of patients stable R5 or
switching from R5 with respect to 10% of stable X4 or
switching from X4 revealed HIV RNA <2,5 copies/ml at
T2. Confirming this result, in the subgroup of 51 subjects
with evaluations at all three time points, patients with
stable R5-tropic strain or with R5 in two out of three
determinations demonstrated a greater control in plasma
replication than stable or prevalent X4-tropic patients; a
24% success rate in terms of complete suppression of
residual replication in stable R5-tropic was observed,
while the seven subjects with stable X4 never showed
controlled replication at a level below 2.5 copies/ml. Sixty-
two percent the subjects with plasma RNA levels below
2,5 copies/ml were stable R5-tropic patients.
These results allow us to suggest that the total amount
of time spent with the R5 condition appears to be rele-
vant for reaching the best control of plasma viraemia,
rather than the current tropism condition. To our know-
ledge, no data are available on this matter, making this
observation the first demonstration of a correlation
between an R5 genotype and a better virologic control
during follow-up in treatment responder patients.
In our cohort, 73 subjects (33.4%) had an X4 strain in
their PBMCs at the first follow-up after treatment initi-
ation; the absolute CD4 count and the CD4 percentage
were higher in R5- than in X4-tropic patients at baseline
and at the follow-up time points. The T0 absolute CD4
count was particularly high in R5-tropic patients,
reaching statistical significance with respect to X4 sub-
jects (p= 0.0216). On the contrary, no significant differ-
ence was found in the follow-up assessments at different
time points in the recovery of CD4+ cells in patients
Table 4 Mixed-effects logistic regression
Plasma RNA under low threshold Coef. Std. Err. z P>z 95% Conf. interval
log10 DNA −1.6098 0.5018 −3.21 0.001 −2.5932 −0.6263
baseline log10 RNA −0.6943 0.3273 −2.12 0.034 −1.3359 −0.0528
X4 −1.4030 0.5493 −2.55 0.011 −2.4795 −0.3265
Time −0.0072 0.0128 −0.56 0.573 −0.0322 0.0178
Intercept 6.3031 2.1489 2.93 0.003 2.0913 10.5150
Group variable: patient. Log likelihood = −143.7488, Wald chi2(4) = 13.44, P = 0.0093.
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harbouring an R5- or X4-tropic virus. This result
confirms those obtained in previous studies showing no
differences in the virological treatment response between
patients harbouring an X4- or R5-tropic virus, although
a poor recovery of CD4 cells has been shown in patients
with an X4-tropic virus at baseline or after an R5 to X4
virus switch [7,11-13,24]. Nevertheless, in our cohort the
mean CD4 count increased in the interval T1 to T2, and
this increase was significantly higher patients harbouring
R5 coreceptor tropism than for X4 tropism (p = 0.0497).
This finding suggests a possible difference in the long-
term course of this disease. Some biases of the study
should be considered. First of all, since viral DNA
sequenced from PBMCs may be a reflection of HIV
archived at different stages of infection, changes in viral
tropism detected in our study may be caused by a sam-
pling issue or by technical reasons in consequence of the
use of population sequencing rather than viral evolution.
To avoid or minimize these biases we repeated twice all
sequences with a false positive rate surrounding the cut-
off values. Additionally, it was not possible to obtain an
analysis of the tropism for all patients at all time points
studied. However, this study analysed numerous viro-
immunological parameters, and a large number of patients
was evaluated at individual time points. In 51 patients, it
was possible to evaluate the various parameters through-
out the course of treatment.
Conclusions
In successfully treated naïve subjects, the tropism of ar-
chived virus was revealed to be stable, but with a substan-
tial rate (15-18%) of subjects switching from one type to
the other over time, despite a viraemia <50 copies/ml. An
R5 tropism and its stability on follow-up were related to
achieving and maintaining very low levels (less than 2.5
copies/ml of plasma) of viral replication in treatment
responder patients, suggesting a relation among viral
tropism and response to treatment in the long term.
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